Effect of daily consumption of whole fruit feijoa powder on metabolic profile: A Randomised Controlled Trial
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Prediabetes is an intermediate state of increased glucose concentrations above the normal range but below the diagnostic threshold for type 2 diabetes (T2D). Adults with overweight and prediabetes are at increased risk of progression to T2D and metabolic imbalance. Feiolix® -a whole-fruit feijoa powder rich in abscisic acid, polyphenols and dietary fibre which may support metabolic health through multiple, potentially complementary pathways.
Objective
To evaluate the effects of low and high-dose Feiolix compared with placebo, on HbA1C, glucagon like peptide (GLP-1) and other metabolic parameters
Methods
Adults aged 21–65 years with prediabetes i.e. glycosylated hemoglobulin (HbA1c) 5.7–6.4% and overweight with body mass index (BMI)- 25.0–29.9 kg/m² were randomised to receive Feiolix-LD (300 mg/day) or Feiolix-HD (1,150 mg/day), or placebo (maltodextrin) for 12 weeks. Anthropometric measurements were obtained monthly, and fasting blood samples were collected at baseline and 12 weeks post intervention. Postprandial blood samples were collected at baseline and 12 weeks. Outcomes included HbA1c, GLP-1, fasting plasma glucose, insulin resistance lipid markers, body weight and BMI. Analyses were conducted using ANCOVA model with baseline values as covariates.
Result
Of 41 individuals screened, 39 were randomised (13 per group); one participant withdrew from the Feiolix-LD. At week 12, HbA1c decreased by 0.5% in the Feiolix-HD and by 0.4% in the Feiolix-LD, with both reductions significantly greater than placebo (p < 0.05); Compared with placebo, Feiolix supplementation significantly lowered fasting plasma glucose, insulin, HOMA-IR, total cholesterol and LDL-cholesterol. The Feiolix-HD attenuated the increase in triglycerides and reduced body weight and BMI by month 2 compared to placebo. GLP-1 concentrations did not differ between groups. However, no change in GLP-1 was observed between the treatments. No treatment-related adverse events were reported.
Conclusion
This study supports the potential of Feiolix supplementation to improve metabolic health, including glycemic and lipid outcomes, with additional benefits for body weight and BMI at the higher dose.
